SLC28A1 and pancreatic neoplasm: To test this hypothesis, we examined the plasma and urinary pharmacokinetic profiles of gemcitabine (dFdC), a fluoro substituted 2′-deoxycytidine chemotherapeutic with high affinity for CNT1 (Km ∼12–36 μmol/L) that is currently used to treat pancreatic cancer and several other solid tumors (43–47).